Illumina, Inc. (NASDAQ:ILMN) Stake Reduced by Douglas Lane & Associates LLC

Douglas Lane & Associates LLC lessened its holdings in shares of Illumina, Inc. (NASDAQ:ILMNGet Rating) by 0.1% in the first quarter, according to its most recent filing with the SEC. The firm owned 315,162 shares of the life sciences company’s stock after selling 420 shares during the quarter. Illumina comprises approximately 1.6% of Douglas Lane & Associates LLC’s holdings, making the stock its 15th largest position. Douglas Lane & Associates LLC owned approximately 0.20% of Illumina worth $110,118,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Asset Dedication LLC boosted its position in Illumina by 75.0% during the 1st quarter. Asset Dedication LLC now owns 77 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 33 shares during the period. Farmers & Merchants Investments Inc. acquired a new stake in shares of Illumina in the first quarter valued at $30,000. Riverview Trust Co acquired a new stake in shares of Illumina in the first quarter valued at $37,000. IronBridge Private Wealth LLC acquired a new stake in shares of Illumina in the fourth quarter valued at $38,000. Finally, Equitec Proprietary Markets LLC acquired a new stake in shares of Illumina in the fourth quarter valued at $43,000. Institutional investors own 86.62% of the company’s stock.

In other news, SVP Charles Dadswell sold 368 shares of the company’s stock in a transaction dated Thursday, April 28th. The stock was sold at an average price of $300.13, for a total transaction of $110,447.84. Following the completion of the sale, the senior vice president now owns 7,427 shares in the company, valued at approximately $2,229,065.51. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Susan H. Tousi sold 250 shares of the company’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $214.85, for a total value of $53,712.50. Following the sale, the senior vice president now owns 41,833 shares of the company’s stock, valued at approximately $8,987,820.05. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 3,092 shares of company stock worth $1,031,322. Insiders own 0.13% of the company’s stock.

Several analysts have recently weighed in on the company. Cowen cut their price objective on Illumina from $506.00 to $492.00 in a report on Friday, May 6th. StockNews.com initiated coverage on Illumina in a report on Thursday, March 31st. They issued a “hold” rating for the company. OTR Global raised Illumina from a “mixed” rating to a “positive” rating in a report on Tuesday, March 29th. Cowen reduced their target price on Illumina from $506.00 to $492.00 in a report on Friday, May 6th. Finally, Citigroup reduced their target price on Illumina from $400.00 to $325.00 in a report on Friday, May 6th. Seven equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $435.92.

Shares of ILMN stock opened at $193.02 on Wednesday. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.85 and a quick ratio of 1.54. Illumina, Inc. has a fifty-two week low of $180.00 and a fifty-two week high of $526.00. The stock’s 50-day moving average is $228.74 and its two-hundred day moving average is $307.89. The firm has a market cap of $30.32 billion, a P/E ratio of 41.96, a PEG ratio of 1.50 and a beta of 1.10.

Illumina (NASDAQ:ILMNGet Rating) last issued its earnings results on Thursday, May 5th. The life sciences company reported $1.07 earnings per share for the quarter, topping the consensus estimate of $0.87 by $0.20. Illumina had a return on equity of 8.37% and a net margin of 15.04%. The company had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.22 billion. During the same period in the prior year, the firm posted $1.89 EPS. The business’s revenue was up 11.9% compared to the same quarter last year. As a group, research analysts expect that Illumina, Inc. will post 4.1 EPS for the current year.

Illumina Profile (Get Rating)

Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

Read More

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.